Alnylam and Dicerna Collaborate to Develop and Commercialize RNAi Therapeutics for Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Lilly Signs a Global Research and License Collaboration with Dicerna for ~$550M


  • The collaboration will explore Alnylam’s ALN-AAT02 and Dicerna’s DCR-A1AT, each in P-I/II development for the treatment of alpha-1 liver disease. Dicerna will lead the global clinical development and commercialization (US only) of its DCR-A1AT and Alnylam’s ALN-AAT02
  • Post P-III completion, Alnylam retains an option to commercialize the selected candidate outside the US. If Alnylam exercises its opt-in right, both the companies will pay royalties to each other based on the commercialization of the product and if it waives its option, Alnylam will receive milestones and royalties while Dicerna retain global rights to commercialize the selected candidate
  • Additionally, companies have completed a non-exclusive IP cross-license agreement for the development and commercialization of Alnylam’s lumasiran and Dicerna’s nedosiran for PH. Under the cross-license agreement, Alnylam will pay royalties to Dicerna on the global sales of lumasiran and Dicerna will pay royalties to Alnylam on global sales of nedosiran

Click here ­to­ read full press release/ article | Ref: Alnylam | Image: Dicerna